Higher levels of an enzyme called GST02 in the most affected neurons in Huntington’s disease could underlie early increases…
Articles by Lindsey Shapiro, PhD
Diminished production in the brain of a protein known as CHCHD2 may contribute to early neurodevelopmental changes that go on…
Clumps of the mutant huntingtin protein, which are the known cause of Huntington’s disease, poke holes in the membrane…
The investigational gene therapy AMT-130 is slowing disease progression for people with early-stage Huntington’s disease, as well as…
More than three months of treatment with WVE-003 safely leads to significant reductions in mutant huntingtin — the protein that…
The effects of Ingrezza (valbenazine) on Huntington’s disease-associated chorea grew increasingly stronger over the course of the…
Daily treatment with Ingrezza (valbenazine) led to sustained reductions in chorea — characterized by involuntary, unpredictable body movements…
The brain of people with pediatric-onset Huntington’s disease show impaired transport of blood sugar, or glucose, and low levels…
Note: This story was updated Jan. 24, 2024, to correct that Takeda is not supporting WVE-003’s development. Wave Sciences…
In 2023, Huntington’s Disease News brought you the latest in scientific breakthroughs and treatment developments related to Huntington’s…